Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.

Doran Ksienski,Elaine S Wai,Nicole Croteau,Leathia Fiorino,Edward Brooks,Zia Poonja,Dave Fenton, Georiga Geller,Mary Lesperance

Clinical Lung Cancer（2019）

引用 66|浏览18

暂无评分

摘要

Treatment interruption due to irAE was associated with a lower median OS compared to continuous PD-1 Ab therapy. Shorter OS seen with severe irAE might reflect the need for improved physician education in irAE treatment algorithms.

查看译文

关键词

Immune related adverse events,Immunotherapy,Real world data

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要